TY - JOUR
T1 - Genome-wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder
AU - Consortium on the Genetics of Schizophrenia (COGS)
AU - Harvey, Philip D.
AU - Sun, Ning
AU - Bigdeli, Tim B.
AU - Fanous, Ayman H.
AU - Aslan, Mihaela
AU - Malhotra, Anil K.
AU - Lu, Qiongshi
AU - Hu, Yiming
AU - Li, Boyang
AU - Chen, Quan
AU - Mane, Shrikant
AU - Miller, Perry
AU - Rajeevan, Nallakkandi
AU - Sayward, Frederick
AU - Cheung, Kei Hoi
AU - Li, Yuli
AU - Greenwood, Tiffany A.
AU - Gur, Raquel E.
AU - Braff, David L.
AU - Brophy, Mary
AU - Pyarajan, Saiju
AU - O'Leary, Timothy J.
AU - Gleason, Theresa
AU - Przygodszki, Ronald
AU - Muralidhar, Sumitra
AU - Gaziano, J. Michael
AU - Concato, John
AU - Zhao, Hongyu
AU - Siever, Larry J.
N1 - Funding Information:
Planning Committee: M. Aslan, M. Antonelli, M. de Asis, M.S. Bauer, M. Brophy, J. Concato, F. Cunningham, R. Freedman, M. Gaziano, T. Gleason, P. D. Harvey, G. Huang, J. Kelsoe, T. Kosten, T. Lehner, J. B. Lohr, S. R. Marder, P. Miller, T. J. O'Leary, T. Patterson, P. Peduzzi, R. Przygodzki, L. Siever, P. Sklar, S. Strakowski, H. Zhao. Executive Committee: M. Brophy, J. Concato, W. Farwell, M. Gaziano, P. D. Harvey, T. Kosten, A. Malhotra, S. Mane, P. Palacios, P. Sklar, L. Siever, H. Zhao. Study Chairs ' Offices: VA Healthcare System, Bronx, NY, included L. Siever (Study Co‐Chair), M. Corsey, L. Zaluda. VA Healthcare System, Miami, FL, included P. D. Harvey (Study Co‐ Chair), J. Johnson (Expert Trainer). CSP Epidemiology Centers: VA Clinical Epidemiology Research Center (CERC), VA Connecticut Healthcare System, West Haven, CT, included J. Concato (Director, Methodological Co‐Principal Proponent), M. Aslan, D. Cavaliere, V. Jeanpaul, A. Maffucci, L. Mancini; the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Jamaica Plain, MA, included M. Gaziano (Director, Methodological Co‐Principal Proponent), J. Deen, G. Muldoon, S. Whitbourne. Study Sites: Albuquerque : J. Canive, L. Adamson, L. Calais, G. Fuldauer, R. Kushner, G. Toney, M. Lackey, A. Mank, N. Mahdavi, G. Villarreal. Atlanta : E. C. Muly, F. Amin, M. Dent, J. Wold. Baltimore : B. Fischer, A. Elliott, C. Felix, G. Gill. Birmingham : P. E. Parker, C. Logan, J. McAlpine. Brockton : L. E. DeLisi, S. G Reece. Charleston : M.B. Hammer, D. Agbor‐Tabie, W. Goodson. Cincinnati : M. Aslam, M. Grainger, Neil Richtand, Alexander Rybalsky. Houston : R. Al Jurdi, E. Boeckman, T. Natividad, D. Smith, M. Stewart, S. Torres, Z. Zhao. Indianapolis : A. Mayeda, A. Green, J. Hofstetter, S. Ngombu, M. K. Scott, A. Strasburger, J. Sumner. Little Rock : G. Paschall, J. Mucciarelli, R. Owen, S. Theus, D. Tompkins. Long Beach : S.G. Potkin, C. Reist, M. Novin, S. Khalaghizadeh. Miami : R. Douyon, J. Johnson, N. Kumar, B. Martinez. Minneapolis : S. R. Sponheim, T. L. Bender, H. L. Lucas, A. M. Lyon, M. P. Marggraf, L. H. Sorensen, C. R. Surerus. Montrose : C. Sison, J. Amato, D. R. Johnson, N. Pagan‐Howard. New York Harbor : L. A. Adler, S. Alperin, T. Leon. Northampton : K. M. Mattocks, N. Araeva, J. C. Sullivan. Palo Alto : T. Suppes, K. Bratcher, L. Drag, E. G. Fischer, L. Fujitani, S. Gill, D. Grimm, J. Hoblyn, T. Nguyen, E. Nikolaev, L. Shere, R. Relova, A. Vicencio, M. Yip. Philadelphia : I. Hurford, S. Acheampong, G. Carfagno. Pittsburgh : G. L. Haas, C. Appelt, E. Brown, B. Chakraborty, E. Kelly, G. Klima, S. Steinhauer. Salisbury : R. A. Hurley, R. Belle, D. Eknoyan, K. Johnson, J. Lamotte. San Diego : E. Granholm, K. Bradshaw, J. Holden, R. H. Jones, T. Le, I. G. Molina, M. Peyton, I. Ruiz, L. Sally. Tacoma : A. Tapp, S. Devroy, V. Jain, N. Kilzieh, L. Maus, K. Miller, H. Pope, A. Wood. Temple : E. Meyer, P. Givens, P. B. Hicks, S. Justice, K. McNair, J. L. Pena, David F. Tharp. Tuscaloosa : L. Davis, M. Ban, L. Cheatum, P. Darr, W. Grayson, J. Munford, D. Smith, B. Whitfield, E. Wilson. Washington DC : A. H. Fanous, S. E. Melnikoff, M. A. Tureson. West Haven : D. D'Souza, K. Forselius, M. Ranganathan, L. Rispoli. Albuquerque, NM, CSP Coordinating Center (for monitoring) : M. Sather (Director), C. Colling, C. Haakenson, D. Krueger. VA Office of Research and Development : T. O'Leary (Chief Research and Development Officer), G. Huang (Director, Cooperative Studies Program), T. Gleason (Director, Clinical Science Research and Development Service), R. Przygodzki (Associate Director for Genomic Medicine, and Acting Director of Biomedical Laboratory Research and Development Service), S. Muralidhar (Senior Scientific Program Manager Genomic Medicine Program, Biomedical and Clinical R&D Services). Dr. Harvey has served as a consultant to multiple pharmaceutical companies and device manufacturers on phase 2 or 3 development; this consulting work has been determined to not be related to the content of the article. The Million Veteran Program is supported by the Office of Research and Development, Department of Veterans Affairs. The Consortium on the Genetics of Schizophrenia (COGS) was supported by grants R01 MH065571, R01 MH065588, R01 MH065562, R01 MH065707, R01 MH065554, R01 MH065578, R01 MH065558, R01 MH86135, and R01 MH094320 from the National Institute of Mental Health. No other authors report any conflicts of interest.
Funding Information:
This research was supported by the Department of Veterans Affairs Cooperative Studies Program (CSP #572), and the Million Veteran Program (MVP–000). The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The authors would like to acknowledge the support of Drs. Timothy O'Leary and Grant Huang for their support in the initiation and maintenance of the scientific efforts of the CSP#572 Project.
Publisher Copyright:
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Cognitive impairment is a frequent and serious problem in patients with various forms of severe mental illnesses (SMI), including schizophrenia (SZ) and bipolar disorder (BP). Recent research suggests genetic links to several cognitive phenotypes in both SMI and in the general population. Our goal in this study was to identify potential genomic signatures of cognitive functioning in veterans with severe mental illness and compare them to previous findings for cognition across different populations. Veterans Affairs (VA) Cooperative Studies Program (CSP) Study #572 evaluated cognitive and functional capacity measures among SZ and BP patients. In conjunction with the VA Million Veteran Program, 3,959 European American (1,095 SZ, 2,864 BP) and 2,601 African American (1,095 SZ, 2,864 BP) patients were genotyped using a custom Affymetrix Axiom Biobank array. We performed a genome-wide association study of global cognitive functioning, constructed polygenic scores for SZ and cognition in the general population, and examined genetic correlations with 2,626 UK Biobank traits. Although no single locus attained genome-wide significance, observed allelic effects were strongly consistent with previous studies. We observed robust associations between global cognitive functioning and polygenic scores for cognitive performance, intelligence, and SZ risk. We also identified significant genetic correlations with several cognition-related traits in UK Biobank. In a diverse cohort of U.S. veterans with SZ or BP, we demonstrate broad overlap of common genetic effects on cognition in the general population, and find that greater polygenic loading for SZ risk is associated with poorer cognitive performance.
AB - Cognitive impairment is a frequent and serious problem in patients with various forms of severe mental illnesses (SMI), including schizophrenia (SZ) and bipolar disorder (BP). Recent research suggests genetic links to several cognitive phenotypes in both SMI and in the general population. Our goal in this study was to identify potential genomic signatures of cognitive functioning in veterans with severe mental illness and compare them to previous findings for cognition across different populations. Veterans Affairs (VA) Cooperative Studies Program (CSP) Study #572 evaluated cognitive and functional capacity measures among SZ and BP patients. In conjunction with the VA Million Veteran Program, 3,959 European American (1,095 SZ, 2,864 BP) and 2,601 African American (1,095 SZ, 2,864 BP) patients were genotyped using a custom Affymetrix Axiom Biobank array. We performed a genome-wide association study of global cognitive functioning, constructed polygenic scores for SZ and cognition in the general population, and examined genetic correlations with 2,626 UK Biobank traits. Although no single locus attained genome-wide significance, observed allelic effects were strongly consistent with previous studies. We observed robust associations between global cognitive functioning and polygenic scores for cognitive performance, intelligence, and SZ risk. We also identified significant genetic correlations with several cognition-related traits in UK Biobank. In a diverse cohort of U.S. veterans with SZ or BP, we demonstrate broad overlap of common genetic effects on cognition in the general population, and find that greater polygenic loading for SZ risk is associated with poorer cognitive performance.
KW - bipolar disorder
KW - cognition
KW - genome-wide association study (GWAS)
KW - impairment
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85076893385&partnerID=8YFLogxK
U2 - 10.1002/ajmg.b.32775
DO - 10.1002/ajmg.b.32775
M3 - Article
C2 - 31872970
AN - SCOPUS:85076893385
SN - 1552-4841
VL - 183
SP - 181
EP - 194
JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
IS - 3
ER -